Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Abilene, Texas


Purpose:

Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye. Stage 2 will begin after 1 month of safety has been evaluated for Stage 1. Stage 2 is a randomized, double-masked, dose-response, sham-controlled evaluation of the safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy from age-related macular degeneration. Patients will be followed for up to 2 years.


Criteria:

Inclusion Criteria: - Geographic atrophy in both eyes due to age-related macular degeneration - Visual acuity between 20/40 to 20/320 Exclusion Criteria: - Known allergy to brimonidine - Uncontrolled systemic disease or infection of the eye - Recent eye surgery or injections in the eye - Female patients who are pregnant, nursing or planning a pregnancy


NCT ID:

NCT00658619


Primary Contact:

Study Director
Medical Director
Allergan


Backup Contact:

N/A


Location Contact:

Abilene, Texas
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.